Brief: Plus Therapeutics Announces Oral Presentation Highlighting Reyobiq™ Clinical And Translational Data Demonstrating Favorable Safety, Survival, And Emerging Immunomodulation In Leptomeningeal Metastases
08/05/2026 13:01
May 8 (Reuters) - Plus Therapeutics Inc PSTV.O: PLUS THERAPEUTICS ANNOUNCES ORAL PRESENTATION HIGHLIGHTING REYOBIQ™ CLINICAL AND TRANSLATIONAL DATA DEMONSTRATING FAVORABLE SAFETY, SURVIVAL, AND EMERGING IMMUNOMODULATION IN LEPTOMENINGEAL METASTASES Source text: ID:nGNX8HMHgr Further company coverage: PSTV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cerenome
See all newsBrief: Cerenome Secures In-Network Agreement With Florida Blue For Cnside® Csf Tumor Cell Enumeration And Molecular Profile Tests
Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cerenome Secures In-Network Agreement With Health Care Service Corporation
Plus Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer